Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.380 | Biomarker | disease | CTD_human | YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. | 20729916 | 2010 | ||||
|
0.380 | Biomarker | disease | BEFREE | Taken together, we provide evidence that YAP1 could represent a novel biomarker gene of cetuximab resistance in HNSCC cell lines. | 24993889 | 2014 | ||||
|
0.380 | AlteredExpression | disease | BEFREE | Ectopic ACTL6A/p63 expression promotes tumorigenesis, while ACTL6A expression and YAP activation are highly correlated in primary HNSCC and predict poor patient survival. | 28041841 | 2017 | ||||
|
0.380 | Biomarker | disease | BEFREE | The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. | 29262850 | 2017 | ||||
|
0.380 | Biomarker | disease | BEFREE | Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. | 29340043 | 2017 | ||||
|
0.380 | Biomarker | disease | BEFREE | Tissue arrays showed that PI3K p110α levels correlated with YAP nuclear localization in HNSCC tumors. | 29598951 | 2018 | ||||
|
0.380 | Biomarker | disease | BEFREE | We also show that unrestrained YAP1 acts as an oncogenic driver in HNSCC, and that targeting YAP1 may represent an attractive precision therapeutic option for cancers harboring genomic alterations in the FAT1 tumor suppressor genes. | 29985391 | 2018 | ||||
|
0.380 | AlteredExpression | disease | BEFREE | <b>Conclusions</b>: Our results indicate that YAP1 overexpression is involved in HNSCC tumorigenesis and verteporfin is a potential therapeutic drug for HNSCC. | 31413738 | 2019 | ||||
|
0.380 | Biomarker | disease | BEFREE | Recent advances in the role of Hippo-YAP pathway in HNSCC have provided evidence that genetic alterations frequent in this type of cancer such as <i>PIK3CA</i> (phosphatidylinositide 3-kinase catalytic subunit alpha) overexpression or FAT1 (FAT atypical cadherin 1) functional loss can result in YAP activation. | 31817001 | 2019 |